Leuprolide plus donepezil may stabilize memory loss in Alzheimer's disease
the ONA take:
According to a new study published in the Journal of Alzheimer's Disease, researchers have found that leuprolide, a drug commonly used for androgen deprivation therapy for patients with prostate cancer, stabilized memory loss for a year in women with Alzheimer's disease.
For the study, researchers enrolled 109 women with mild to moderate Alzheimer's disease. Some women were treated with high-dose leuprolide acetate and donepezil, an acetylcholinesterase inhibitor that treats symptoms of Alzheimer's disease.
Other patients received an acetylcholinesterase inhibitor plus low-dose leuprolide or placebo. Results showed that those treated with donepezil and high-dose leuprolide had nearly no decline in their ADAS-cog score, a memory test, while those treated with an acetylcholinesterase inhibitor plus low-dose leuprolide or placebo experienced declines after 1 year.
Previous studies have suggested the leuprolide has protective benefits for Alzheimer's disease. One study found that men treated with leuprolide for prostate cancer were 34-55% less likely to develop Alzheimer's disease compared with men who did not receive the injection.
The researchers suggest that this promising drug combination should be tested in patients with early and late stages of the disease, but because the company that initially conducted this research is now out of business, it is unclear whether this therapy will be further developed.
Leuprolide stabilized memory loss for a year in women with Alzheimer's disease.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
- Radiotherapy is Essential in Treating Brain Tumors But Associated With Significant Adverse Events
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|